Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension

• Status: Recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of a 4-week fludrocortisone (FLU) treatment on systolic blood pressure depression after 5 minutes of active orthostatism in patients with neurogenic orthostatic hypotension (HON) symptomatic, despite treatment with non-drug measures with or without midodrine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H.A.C. PHARMA
• Treatments: Fludrocortisone

Criteria

Inclusion Criteria:

• Diagnosis of orthostatic hypotension (HO), ie a blood pressure drop> 20 and / or 10 mmHg within 3 minutes after active and symptomatic lifting

• Patient suffering from a neurological disease

• orthostatic neurogenic hypotension persistent and symptomatic despite non-drug measures

Exclusion Criteria:

• Hypersensitivity to FLU or any of its excipients

• non orthostatic neurogenic hypotension

• History of proven heart failure

• History of left ventricular systolic dysfunction

• Uncompensated hypokalemia

• Patient with poorly balanced Grade 3 hypertension

• Pregnant patient at the time of inclusion

• Nursing patient